BioMarin Pharmaceutical Inc. (BMRN) Stock

About BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc. is led by CEO Alexander Hardy, employs 3,221 people, headquartered in San Rafael, US, publicly traded since 1999.

BioMarin Pharmaceutical Inc. (BMRN) stock trades at $55.95 with a market capitalization of $10.83B. The stock is valued at a price-to-earnings (P/E) ratio of 151.42, price-to-book of 1.76, price-to-sales of 3.26. Over the past 52 weeks the stock has ranged between $49.26 and $70.98, and currently trades 21.2% below its 52-week high.

On profitability, BioMarin Pharmaceutical Inc. generates a return on equity (ROE) of 1.18%, return on capital employed of 2.72%, an operating margin of 16.55%, a net profit margin of 2.14%.

BioMarin Pharmaceutical Inc. by the numbers, 2016–2025

Between 2016 and 2025 BioMarin Pharmaceutical Inc. reported revenue of $1.1B rising to $3.2B, a change of +188.4% across 10 years. Compounded, revenue has grown 11.6% a year over five years, 15.4% over three, 12.9% over the last twelve months. Net profit rose to $349.0M.

Operating margin went from -71.9% in 2016 to 16.6% in 2025, a gain of 88.5 percentage points. The most recent net margin is 2.14%. On a trailing twelve-month basis to Jun '26, revenue is $3.4B and net profit $73.0M.

Borrowings fell from $683.0M to $643.0M, cash on hand is $2.2B, cash from operations was $828.0M in the latest year, positive in 8 of the last 10.

Return on equity has averaged 3.6% over five years, and was 5.7% in the most recent year.

The share price itself has compounded at -7.3% a year over five years, -12.8% over three, 4.5% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

BioMarin Pharmaceutical Inc. (BMRN) — frequently asked questions